your are using an old version of
Internet Explorer, please use
the new Edge browser instead of it
Failure to control BVD in endemically infected herds could be costing up to 169 litres2 of milk per animal, per lactation.
As BVD eradication programmes progress, farmers may be starting to think about the continuing need to keep their guard up.
Evidence shows that comprehensive biosecurity is rarely achievable for cattle herds.6,7
The ADVANCE study is the first to evaluate the impact of BVD in an endemically infected dairy farm, using vaccination to create a protected control group within the herd.
It demonstrated that those cattle not protected against BVD had individual daily milk yields of up to 1.8 litres a day less than vaccinated cows in early lactation2.
*DIM 8-102 = 94 days
**Vaccine, labour, equipment etc
***Including animals not contributing to BMT
Four dairy farms across three countries* fulfilled the following criteria:
*UK, Italy and France
Study herds (all animals over 10 months of age) randomly allocated into two groups*, irrespective of current reproductive or lactation status:
*Both groups remained together and experienced the same farm management. Farm and lab personnel were blinded to study groups
Data collected over 365 day study period:
Safeguard their milk production by vaccinating with Bovela®
The ADVANCE study is Europe’s biggest dairy study, which analysed data from 1197 animals, representing 1559 lactations
The majority of countries with systematic BVD control programmes without vaccination have reported severe economic damage from reintroduction of BVDV into cattle populations that have become seronegative, and vulnerable, following the removal of PIs.15
Many countries have national BVD control programmes in place that rely on widespread testing and culling of persistently infected (PI) animals. The eventual result of this is increasingly susceptible and naïve herds.
With decreasing natural immunity and the ever-present threat of infection, annual vaccination with Bovela® protects these herds against the devastating effects of BVD outbreaks.13,14
1. Fourichon et al. (2005) Quantification of economic losses consecutive to infection of a dairy herd with bovine viral diarrhoea virus. Prev Vet Med. 72: 177–181 2. Schmitt–van de Leemput et al. (2020) Comparison of milk production of dairy cows vaccinated with a live double deleted BVDV vaccine and non-vaccinated dairy cows cohabitating in commercial herds endemically infected with BVD virus. PLoS ONE 15(10): e0240113 3. Laureyns et al. (2013) Association Between Herd Exposure to BVDV-infection and Bulk Milk Somatic Cell Count of Flemish Dairy Farms. Prev Vet Med. 109: 148–151 4. Machado et al. (2016) Bovine Viral Diarrhoea Virus (BVDV) in Dairy Cattle: A Matched Case-Control Study. Trans and Emerg Dis. 63: e1–e13 5. Maris et al. (2018) A bovine viral diarrhea virus type 2a infection on a Belgian dairy farm. Vlaams Dierg Tijd. 87: 269-274 6. Barrett et al. (2020) Herd level factors associated with detection of calves persistently infected with bovine viral diarrhoea virus (BVDV) in Irish cattle herds with negative herd status (NHS) during 2017. Prev. Vet. Med. 179: 104990 7. BIAH (2020) 20% of closed herds buy in bulls. National BVD Survey, January 2020 8. Moerman (2011) Clinical consequences of a bovine virus diarrhea virus infection in a dairy herd: A longitudinal study. Vet Quart. (16)2: 115-9 9. Houe (2003) Economic impact of BVDV infection in dairies. Biologicals 31: 137–143 10. Summary of Product Characteristics, Bovela® lyophilisate and solvent for suspension for injection for cattle, Nov 2020 11. Meyers et al. (2007) Bovine viral diarrhea virus: prevention of persistent fetal infection by a combination of two mutations affecting Erns RNase and Npro protease. J Virology 3327–3338 12. Roth et al. (2017) Comparison of humoral and T-cell-mediated immune responses to a single dose of Bovela® live double deleted BVDV vaccine or to a field BVDV strain. Vet Immunol and Immunopath. 187: 20–27 13. Gethmann et al. (2019) An Epidemiological and Economic Simulation Model to Evaluate Strategies for the Control of Bovine Virus Diarrhea in Germany. Frontiers in Veterinary Science 6: 406 14. Moennig (2016) BVDzero Web Congress, BIAH 2016 15. Metcalfe (2019) An Update on the Status of BVD Control and Eradication in Europe. J Vet Sci Med. 7: 1.
Bovela® lyophilisate and solvent for suspension for injection for cattle contains modified live BVDV-1, non-cytopathic parent strain KE-9: 104.0–106.0 TCID50, modified live BVDV-2, non-cytopathic parent strain NY-93: 104.0–106.0 TCID50. UK: POM-V. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd, RG12 8YS, UK. Tel: 01344 746960 (sales) or 01344 746957 (technical). Email: firstname.lastname@example.org. Bovela® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence. ©2020 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Nov 2020. BOV-0273-2020. Use Medicines Responsibly.